AlzeCure Pharma AB (”AlzeCure” or ”The Company”) (FN STO: ALZCUR), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer’s disease and pain, today announced that the company will participate in Aktiespararna's Aktiedagen in Stockholm event on September 15. CEO Martin Jönsson will give a corporate presentation and provide an update on the company's recently announced out-licensing and collaboration agreements with Eli Lilly and QuantumCell relating to AlzeCure’s Alzheimer's disease projects.
Presentation time: 16:25 CEST
Venue: Birger Jarl Konferens, Birger Jarlsgatan 61 A, Stockholm, Sweden
The live broadcast is available via the following link: https://invitepeople.com/public/events/fcf16089a1/pages/aea62aebea
The presentation will also be available on the company's website afterwards: https://www.alzecurepharma.se/en/presentations-and-interviews/
For more information about the event and to register to attend the Birger Jarl Conference in Stockholm, please see here: https://www.aktiespararna.se/aktiviteter/aktiedagen-i-stockholm-68175
